Jun 17 2019 by Business Insider
A controversial blood-transfusion startup called Ambrosia was offering to fill a person's veins with the blood of young people
for $8,000, despite little to no hard evidence that the procedure has any benefits.
On the heels of a warning from federal regulators in February,
Ambrosia said on its website that it had stopped giving the procedure.
But on Monday, Ambrosia's founder told a potential customer that the company was back up and running in two cities: San Francisco and Tampa, Florida,...
Request a feature